Drug Delivery

NANOSCALE COMPLEXES – A Novel Nanotechnology-Based Platform to Optimize Combination Cancer Therapies: Rational Development & Improved Delivery Using CombiPlex®

Barry D. Liboiron, PhD; Arthur C. Louie, MD; et al describe how CombiPlex addresses the challenges facing the traditional development path of many contemporary drug combinations and provide clinical proof-of-principle evidence that this approach can yield marked improvements in efficacy and patient outcomes.

EXCLUSIVE ONLINE CONTENT

12/17/2018

Croda Acquires Biosector; Strengthens Pharmaceutical Offering

Croda International Plc, the speciality chemical company that creates high performance ingredients and technologies relied upon by industry and consumers globally, recently announced that it has strengthened its pharmaceutical offering by signing a definitive agreement with Brenntag Nordic A/S to acquire Brenntag Biosector (Biosector).

12/11/2018

Cambrex Expands Analytical Capabilities

Cambrex Corporation recently announced it is investing $1 million at its High Point, NC, site to fit out 1,300 sq ft of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical research and development scientists pursuant to this project.

11/12/2018

Enable Injections Enters Strategic Partnerships With UCB & Apellis

Enable Injections, Inc., a patient-centric drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, recently announced it has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB.